HUTCHMED’s H1 2024 interim results require investors to look beyond the headline group revenue figures to the growth of the company’s underlying drug product portfolio which was buoyed by the strong commercial uptake of Fruzaqla in the US market. Total in-market sales of HUTCHMED’s products grew 140% (145% CER) YoY to $243m, translating into a rise of consolidated revenues to HUTCHMED of 59% (64% CER) YoY to $128m. This growth was catalysed by the uptake of Fruzaqla, which generated H1 2024 sale ....
